Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Conditions
Brief summary
56-day survival from the time of diagnosis
Detailed description
30-day, 45-day, 56-day (any type of cancer), 90-day survival (early survival) from time of diagnosis; Survival status at hospital discharge for initial hospital admission for sHLH; Number of participants achieving HLH disease response by Day 29 (modified HLH-2004 criteria and biomarker criteria)., HLH disease response is defined as a participant who achieves complete response, modified CR, partial response, or HLH improvement; Incidence of treatment-emergent adverse events
Interventions
DRUGELA026
Sponsors
Electra Therapeutics Inc.
Eligibility
Sex/Gender
All
Age
0 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 56-day survival from the time of diagnosis | — |
Secondary
| Measure | Time frame |
|---|---|
| 30-day, 45-day, 56-day (any type of cancer), 90-day survival (early survival) from time of diagnosis; Survival status at hospital discharge for initial hospital admission for sHLH; Number of participants achieving HLH disease response by Day 29 (modified HLH-2004 criteria and biomarker criteria)., HLH disease response is defined as a participant who achieves complete response, modified CR, partial response, or HLH improvement; Incidence of treatment-emergent adverse events | — |
Countries
Germany, Italy, Netherlands, Spain
Outcome results
None listed